Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.42|
|52 Week High||US$3.12|
|52 Week Low||US$15.00|
|1 Month Change||-1.16%|
|3 Month Change||-32.68%|
|1 Year Change||-71.04%|
|3 Year Change||-77.98%|
|5 Year Change||n/a|
|Change since IPO||-72.77%|
Recent News & Updates
|ATNX||US Biotechs||US Market|
Return vs Industry: ATNX underperformed the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: ATNX underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: ATNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ATNX's weekly volatility (8%) has been stable over the past year.
About the Company
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Athenex Fundamentals Summary
|ATNX fundamental statistics|
Is ATNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATNX income statement (TTM)|
|Cost of Revenue||US$78.85m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.56|
|Net Profit Margin||-121.12%|
How did ATNX perform over the long term?See historical performance and comparison
Is Athenex undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATNX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATNX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ATNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATNX is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.2x).
How is Athenex forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATNX's revenue (7.7% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: ATNX's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATNX is forecast to be unprofitable in 3 years.
How has Athenex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATNX is currently unprofitable.
Growing Profit Margin: ATNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATNX is unprofitable, and losses have increased over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare ATNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ATNX has a negative Return on Equity (-87.05%), as it is currently unprofitable.
How is Athenex's financial position?
Financial Position Analysis
Short Term Liabilities: ATNX's short term assets ($213.1M) exceed its short term liabilities ($62.9M).
Long Term Liabilities: ATNX's short term assets ($213.1M) exceed its long term liabilities ($176.2M).
Debt to Equity History and Analysis
Debt Level: ATNX's debt to equity ratio (87.8%) is considered high.
Reducing Debt: ATNX's debt to equity ratio has increased from 27% to 87.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATNX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ATNX has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 20% each year.
What is Athenex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Johnson Lau (61 yo)
Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...
CEO Compensation Analysis
Compensation vs Market: Johnson's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Johnson's compensation has been consistent with company performance over the past year.
Experienced Management: ATNX's management team is considered experienced (3.6 years average tenure).
Experienced Board: ATNX's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ATNX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
Athenex, Inc.'s employee growth, exchange listings and data sources
- Name: Athenex, Inc.
- Ticker: ATNX
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$361.809m
- Shares outstanding: 109.31m
- Website: https://www.athenex.com
Number of Employees
- Athenex, Inc.
- Conventus Building
- Suite 600
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:03|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.